Health Care Technology
Company Overview of Schrödinger, LLC
Schrödinger, LLC develops chemical simulation software for use in pharmaceutical and biotechnology research. The company provides products ranging from general molecular modeling programs to a suite of drug design software, including ligand- and structure-based methods. It also provides products in various research areas, including small molecule modeling and simulations, macromolecular modeling and simulations, lead discovery, lead optimization, and visualization and automation. The company’s software allows scientists to accelerate their research and development activities, as well as to make novel discoveries. It serves pharmaceutical and biotech companies, universities, non-profit instit...
101 S.W. Main Street
Portland, OR 97204
Founded in 1990
Key Executives for Schrödinger, LLC
Vice President and General Counsel
Head of US Non-Commercial Sales and Senior Vice President of Marketing
Managing Director and Senior Vice President
Compensation as of Fiscal Year 2014.
Schrödinger, LLC Key Developments
Schrödinger Inc. and Professor Mark E. Thompson Announce Research Collaboration to Enable Computer-Aided Design of Organic Semiconductor Materials
Jun 27 13
Schrödinger Inc. and Dr. Mark E. Thompson, Professor of Chemistry at the University of Southern California, announced their joint research collaboration to advance the development and design of organic semiconductor materials through use of atomic-scale simulations. Organic semiconductors are a class of materials that have a wide range of electronic device applications, including organic solar cells and detectors, organic light-emitting diodes (OLEDs), and thin-film transistors. Evaluating expansive chemical space to identify good synthetic targets for organic semiconductors is a challenge that limits the rate of new organic materials development. Schrödinger has previously developed software tools for the discovery of new drug candidates through a method known as virtual screening, which involves the use of high-throughput simulation techniques to predict the candidate systems' chemical properties followed by ranking to identify the most promising lead systems. One of the focuses of this collaboration is to leverage these virtual screening methods for the discovery of novel organic semiconductor materials. Schrödinger's Materials Science Suite 1.0 is available now and provides atomic-scale simulation capabilities for chemical systems used in a wide range of technological applications, including optoelectronics, functional additives, engineered catalysts, and reactive precursors.
BT Group plc and Schrodinger, Inc. Joins to Accelerate the Process of Drug Discovery and Development
May 3 13
BT Group plc and Schrodinger Inc. announced that the two companies are now working together to accelerate the process of drug discovery and development using the BT for Life Sciences cloud platform and Schrodinger's powerful scientific software applications. As part of the joint initiative, Schrodinger becomes a Strategic Member of the BT for Life Sciences partner ecosystem, helping provide research solutions to scientists on a global basis. Schrodinger's software tools will be integrated into BT for Life Sciences as part of BT's R&D Workbench environment. Built on the BT Cloud Compute platform and unveiled at the 10(th) Annual BioIT World meeting last year, BT for Life Sciences is the first cloud service designed to enable collaboration within the life sciences industry for increased productivity in discovery, research and development. One of Schrodinger's key applications, hosted Seurat, will soon be available on the BT Cloud Compute Platform. This application contains tools that help researchers in the discovery and optimization of drug research and provides a means for sharing real-time analysis across the organization. Using the BT platform, Schrodinger can easily integrate data and scientific business processes, enhancing the early discovery process so that ultimately better compounds can be brought to the clinic faster. Because BT for Life Sciences was developed as a secure and segregated platform for scientists, it will enable Schrodinger to work with major pharmaceutical companies and other biotech organizations that need faster and more innovative approaches to drug discovery and development. In the past, researchers would typically provide the IT department with the requirements for each in silico experiment, which could mean a delay in research and discovery as the equipment was purchased and the platform built. Using BT's cloud services for Life Sciences, Schrodinger can now offer their applications quickly and easily with a click-to-launch approach that uses secure, compliant, and scalable cloud computing, storage and databanks, in order to process demanding scientific analysis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|